CancerDrs Find care

Lung Cancer clinical trials

300 actively recruiting lung cancer trials in the United States. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Trials focus on targeted therapies, immunotherapy, and combination regimens.

Data from ClinicalTrials.gov · last refreshed · Lung Cancer stats on SEER

61
Phase 1
102
Phase 2
40
Phase 3
97
Other

Lung Cancer by the numbers (U.S.)

226,650
Estimated new cases (2025)
124,730
Estimated deaths (2025)
28.1%
5-year relative survival
71
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse lung cancer trials by state

Texas 131 California 114 New York 102 Florida 100 Virginia 76 Massachusetts 70 Michigan 70 Ohio 70 Pennsylvania 68 Tennessee 66 Illinois 65 Maryland 59 Missouri 55 New Jersey 55 Georgia 53 Washington 52 Colorado 51 North Carolina 45 Oregon 43 Minnesota 42 Arizona 41 Kentucky 35 Wisconsin 33 Indiana 32 Utah 31 Connecticut 28 Arkansas 27 Nebraska 26 District of Columbia 23 South Carolina 23 Iowa 22 Kansas 22 Alabama 21 Oklahoma 21 Nevada 18 Louisiana 17 New Mexico 15 Maine 14 Mississippi 14 New Hampshire 14 South Dakota 14 Idaho 13 Delaware 12 Hawaii 12 Montana 12 North Dakota 11 Alaska 10 Rhode Island 10 West Virginia 10 Vermont 9 Wyoming 4

Top trials by phase + site coverage

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Locations:
  • Veterans Administration Medical Center - Birmingham — Birmingham, Alabama
  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
  • Thomas Hospital — Fairhope, Alabama

+ 1198 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting NIH

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04402788
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Katmai Oncology Group — Anchorage, Alaska
  • Cancer Center at Saint Joseph's — Phoenix, Arizona

+ 412 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632327
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Cancer Center at Saint Joseph's — Phoenix, Arizona
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona

+ 374 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Locations:
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
  • Tower Cancer Research Foundation — Beverly Hills, California
  • Veterans Affairs Loma Linda Healthcare System — Loma Linda, California

+ 223 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…

Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Locations:
  • Children's Hospital of Alabama — Birmingham, Alabama
  • Providence Alaska Medical Center — Anchorage, Alaska
  • Kingman Regional Medical Center — Kingman, Arizona

+ 216 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…

Sponsor: Pfizer
NCT ID: NCT07144280
Locations:
  • Alabama Oncology — Alabaster, Alabama
  • Alabama Oncology — Bessemer, Alabama
  • Alabama Oncology, Bruno Cancer Center — Birmingham, Alabama

+ 111 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Locations:
  • Clinical Study Site — Chandler, Arizona
  • Clinical Study Site — Phoenix, Arizona
  • Clinical Study Site — Hot Springs, Arkansas

+ 86 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…

Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Locations:
  • Clearview Cancer Institute — Huntsville, Alabama
  • Infirmary Cancer Care — Mobile, Alabama
  • The University of Arizona Cancer Center - North Campus — Tucson, Arizona

+ 75 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary en…

Sponsor: Summit Therapeutics
NCT ID: NCT05899608
Locations:
  • Banner University Medical Center — Phoenix, Arizona
  • TMC Healthcare — Tucson, Arizona
  • University of Arkansas — Little Rock, Arkansas

+ 68 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Locations:
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona
  • University of Arkansas for Medical Sciences — Little Rock, Arkansas
  • UC San Diego Health System - Encinitas — Encinitas, California

+ 55 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable gen…

Sponsor: AstraZeneca
NCT ID: NCT07291037
Locations:
  • Research Site — Chandler, Arizona
  • Research Site — Gilbert, Arizona
  • Research Site — Goodyear, Arizona

+ 47 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…

Sponsor: AbbVie
NCT ID: NCT04928846
Locations:
  • University of Alabama at Birmingham - Main /ID# 247074 — Birmingham, Alabama
  • Ironwood Cancer & Res Ctr /ID# 262446 — Chandler, Arizona
  • Mayo Clinic Arizona /ID# 255858 — Phoenix, Arizona

+ 47 more sites in the U.S.

View on ClinicalTrials.gov →

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20